CC BY-NC-ND 4.0 · Journal of Child Science 2017; 07(01): e14-e18
DOI: 10.1055/s-0037-1604024
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Functional Status in a Teenager with Phenylketonuria from the ICF Perspective

Hasan Bingöl
1   Vocational School of Health, Department of Therapy and Rehabilitation, Mus Alparslan University, Mus, Turkey
Mintaze Kerem Günel
2   Division of Health Science, Department of Physiotherapy and Rehabilitation, Hacettepe University, Ankara, Turkey
› Institutsangaben
Weitere Informationen


17. Mai 2017

28. Mai 2017

29. Juni 2017 (online)


Objective The case aims to present a teenager with phenylketonuria in terms of functional status, by using the World Health Organization's International Classification of Functioning, Disability, and Health (ICF) perspective.

Case Description A 17-year-old teenager with phenylketonuria, classified level V in accordance with the Functional Mobility Scale, was recruited in this study. To exhibit body structure, functional status, participation, activity, and environmental and individual factors, assessment tools classified according to ICF for Children and Youth major categories were implemented.

Result After the assessment tools were applied, we found various problems ranging from body structure, function, and activity, to participation. In addition to these problems, there were cognitive problems as well.

Conclusion Despite various physical problems, the teenager suffered from cognitive problems more, that is, compared with physical problems in the teenager with phenylketonuria, cognitive problems constituted a bigger barrier to participation in daily life.


At the time this article was written, Hasan Bingöl was a student at Institute of Health Science and Teaching Assistant at Mus Alparslan University.

  • References

  • 1 Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002; 14 (06) 702-706
  • 2 Vockley J, Andersson HC, Antshel KM. , et al; American College of Medical Genetics and Genomics Therapeutics Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014; 16 (02) 188-200
  • 3 Keil S, Anjema K, van Spronsen FJ. , et al. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics 2013; 131 (06) e1881-e1888
  • 4 Harding CO, Winn SR, Gibson KM, Arning E, Bottiglieri T, Grompe M. Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU). J Inherit Metab Dis 2014; 37 (05) 735-743
  • 5 Sampson J, Groshong M, Parilo DM. What nurses need to know about PKU. Nursing 2016; 46 (08) 66-67
  • 6 Guest JF, Bai JJ, Taylor RR, Sladkevicius E, Lee PJ, Lachmann RH. Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet. J Intellect Disabil Res 2013; 57 (06) 567-579
  • 7 Herrmann ME, Brösicke HG, Keller M, Mönch E, Helge H. Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report. Eur J Pediatr 1994; 153 (07) 501-503
  • 8 Acosta PB, Yannicelli S, Marriage B. , et al. Nutrient intake and growth of infants with phenylketonuria undergoing therapy. J Pediatr Gastroenterol Nutr 1998; 27 (03) 287-291
  • 9 McBurnie MA, Kronmal RA, Schuett VE, Koch R, Azeng CG. Physical growth of children treated for phenylketonuria. Ann Hum Biol 1991; 18 (04) 357-368
  • 10 U.S. National Library of Medicine. Genetics Home Reference. Phenylketonuria. 2012. Available at
  • 11 Holm VA, Kronmal RA, Williamson M, Roche AF. Physical growth in phenylketonuria: II. Growth of treated children in the PKU collaborative study from birth to 4 years of age. Pediatrics 1979; 63 (05) 700-707
  • 12 Al-Qadreh A, Schulpis KH, Athanasopoulou H, Mengreli C, Skarpalezou A, Voskaki I. Bone mineral status in children with phenylketonuria under treatment. Acta Paediatr 1998; 87 (11) 1162-1166
  • 13 Allen JR, Baur LA, Waters DL. , et al. Body protein in prepubertal children with phenylketonuria. Eur J Clin Nutr 1996; 50 (03) 178-186
  • 14 Felder E, Protasi F, Hirsch R, Franzini-Armstrong C, Allen PD. Morphology and molecular composition of sarcoplasmic reticulum surface junctions in the absence of DHPR and RyR in mouse skeletal muscle. Biophys J 2002; 82 (06) 3144-3149
  • 15 Mutlu A, Kelgökmen Z. . Available at
  • 16 CanChild Centre for Childhood Disability Research. Available at
  • 17 Gorton III GE, Stout JL, Bagley AM, Bevans K, Novacheck TF, Tucker CA. Gillette Functional Assessment Questionnaire 22-item skill set: factor and Rasch analyses. Dev Med Child Neurol 2011; 53 (03) 250-255
  • 18 Wong V, Wong S, Chan K, Wong W. Functional Independence Measure (WeeFIM) for Chinese children: Hong Kong Cohort. Pediatrics 2002; 109 (02) E36
  • 19 Graham HK, Harvey A, Rodda J, Nattrass GR, Pirpiris M. The Functional Mobility Scale (FMS). J Pediatr Orthop 2004; 24 (05) 514-520
  • 20 Hidecker MJC, Paneth N, Rosenbaum PL. , et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011; 53 (08) 704-710
  • 21 Manual Ability Classification System for Children with Cerebral Palsy 4–18 years. Available at
  • 22 Barnes D, Linton JL, Sullivan E. , et al. Pediatric Outcome Data Collection Instrument Scores in Ambulatory Children with Cerebral Palsy. J Pediatr Orthop 2008; 28: 97-102
  • 23 Küçükkasap T. To Define Treatment, Diagnosis, Intervention and Screening in Phenylketonuria Disease in Turkey [master thesis]. 2013 :7